You are here:
Grade II to IV acute graft-versus-host disease (aGvHD).
No judgement
18,500,000.00
Clinical trials
Itacitinib
Oncology and Hematology
Graft versus Host
Incyte
Oral
Tablet
Intermural (MSZ)
Janus kinase 1 (JAK1)-inhibitor.
New medicine
2019
2020
Yes
Phase III gestart, GRAVITAS-301, JAK1 inhibitor icm corticosteroids.
Ciclosporin en corticosteroiden (en zodra geregistreerd Ibrutinib)
continuous
1 times a day
< 250
Market share is generally not included unless otherwise stated.
400-500 allogene stamceltransplantaties per jaar. 50% kans op acute GvHD.
74,000.00
Medicijnkosten.nl
Geschatte maximale kosten op basis van kosten en behandelschema ibrutinib is 74.000 euro per patient per jaar.
This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.
There is currently nothing known about off label use.
No
Clinicaltrials.gov
Er lopen wel meerdere studies voor andere aandoeningen maar nog niet in phase III.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines